Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Open accessThe DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
Leber's congenital amaurosis (LCA) is a group of inherited blinding diseases with onset during childhood. One form of the disease, LCA2, is caused by mutations in the retinal pigment epithelium-specific 65-kDa protein gene (RPE65). We investigated the safety of subretinal delivery of a recombinant adeno-associated virus (AAV) carrying RPE65 complementary DNA (cDNA) (ClinicalTrials.gov number, NCT00516477 [ClinicalTrials.gov]). Three patients with LCA2 had an acceptable local and systemic adverse-event profile after delivery of AAV2.hRPE65v2. Each patient had a modest improvement in measures of retinal function on subjective tests of visual acuity. In one patient, an asymptomatic macular hole developed, and although the occurrence was considered to be an adverse event, the patient had some return of retinal function. Although the follow-up was very short and normal vision was not achieved, this study provides the basis for further gene therapy studies in patients with LCA.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The main disadvantage of this approach is the surgery itself. Traditional vitrectomy complications such as cataract, IOP rise and retinal tears, as well as subretinal injection-related complications such as a macular hole.4,87,88”
From Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses (2022) · cites this paper as [88]
In the citing paper
“Many current retinal gene therapy trials adopt a standardized immunosuppression protocol up to 21 days post-treatment, which may ameliorate this immune response in humans.6,7,40”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [40]
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [42]
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [11]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Self-citationIdiopathic Senile Macular Hole: Its Early Stages and Pathogenesis
Gass, J. D. M. (1988) · Archives of Ophthalmology · doi:10.1001/archopht.1988.01060130683026 · Cited by 992
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Self-citationMutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Self-citationAcland, G. M., Aguirre, G. D., Bennett, J., Aleman, T. S., Cideciyan, A. V., Bennicelli, J., Dejneka, N. S., Pearce-Kelling, S. E., Maguire, A. M., Palczewski, K., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.008 · Cited by 477
Self-citationRpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Self-citationNatural Course of Retinitis Pigmentosa Over a Three-Year Interval
Berson, E. L., Sandberg, M. A., Rosner, B., Birch, D. G., & Hanson, A. H. (1985) · American Journal of Ophthalmology · doi:10.1016/0002-9394(85)90351-4 · Cited by 321
Jacobson, S. G., Aleman, T. S., Cideciyan, A. V., Sumaroka, A., Schwartz, S. B., Windsor, E. A. M., Traboulsi, E. I., Heon, E., Pittler, S. J., Milam, A. H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500646102 · Cited by 274
Self-citation
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Aguirre GD, 1998, Mol Vis, 4, 23
- 10.1038/88327 · DOI
- Fosnaugh JS, 1992, Methods Find Exp Clin Pharmacol, 14, 545
Cited by
Items 501–600 of 1,031
Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
N. Sahni, J., Angi, M., Irigoyen, C., Angi, M., Semeraro, F., R. Romano, M., Parmeggiani, F., & Parmeggiani, F. (2011) · Current Genomics · doi:10.2174/138920211795860062 · Cited by 69
“Three human clinical trials using AAV serotype 2 reported their findings separately in 9 patients in 2008 [39-41].”
BackgroundOptogenetic stimulation of the auditory pathway for research and future prosthetics
Moser, T. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.01.004 · Cited by 72
Banin, E., Bandah-Rozenfeld, D., Obolensky, A., Cideciyan, A. V., Aleman, T. S., Marks-Ohana, D., Sela, M., Boye, S., Sumaroka, A., Roman, A. J., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.047 · Cited by 69
Kumaran, N., Michaelides, M., Smith, A. J., Ali, R. R., & Bainbridge, J. W. B. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy005 · Cited by 68
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 78
Assessment of Adeno-Associated Virus Serotype Tropism in Human Retinal Explants
Wiley, L. A., Burnight, E. R., Kaalberg, E. E., Jiao, C., Riker, M. J., Halder, J. A., Luse, M. A., Han, I. C., Russell, S. R., Sohn, E. H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.179 · Cited by 68
“expression of RPE65 protein in humans, and to result in improvement in visual acuity, pupillary light reflex, visual fields, and ambulatory vision that was closely correlated with the area of the retina that received treatment.(6) Further, no adverse immune responses or extra-ocular spread of AAV2-RPE65 was detected.”
BackgroundSelf-citationLeber Congenital Amaurosis (LCA): Potential for Improvement of Vision
Cideciyan, A. V., & Jacobson, S. G. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-26672 · Cited by 74
Wang, X., Yu, C., Tzekov, R. T., Zhu, Y., & Li, W. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-1304-1 · Cited by 68
Britten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Gene editing and its applications in biomedicine
Li, G., Li, X., Zhuang, S., Wang, L., Zhu, Y., Chen, Y., Sun, W. C., Wu, Z., Zhou, Z. L., Chen, J., et al. (2022) · Science China Life Sciences · doi:10.1007/s11427-021-2057-0 · Cited by 77
“deliver the gene encoding a 65-kD retinal pigment epithelium-associated protein (RPE65) into the eyes of patients carrying biallelic RPE65 recessive mutations (Bainbridge et al., 2008; Cideciyan et al., 2009; Maguire et al., 2008).”
BackgroundStone, E. M., Cideciyan, A. V., Aleman, T. S., Scheetz, T. E., Sumaroka, A., Ehlinger, M. A., Schwartz, S., Fishman, G. A., Traboulsi, E. I., Lam, B. L., et al. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2010.330 · Cited by 75
Self-citationNeuroprotective Strategies for the Treatment of Inherited Photoreceptor Degeneration
Trifunovic, D., Sahaboglu, A., Kaur, J., Mencl, S., Zrenner, E., Ueffing, M., Arango-Gonzalez, B., & Paquet-Durand, F. (2012) · Current Molecular Medicine · doi:10.2174/156652412800620048 · Cited by 67
“Indeed, gene therapy has been shown to be feasible in genetically well-defined cases when applied in a specific time frame [14-18].”
BackgroundResults at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy
Pennesi, M. E., Weleber, R. G., Yang, P., Whitebirch, C., Thean, B., Flotte, T. R., Humphries, M., Chegarnov, E., Beasley, K. N., Stout, J. T., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.014 · Cited by 68
Moreno, M. L., Mérida, S., Bosch‐Morell, F., Miranda, M., & Villar, V. M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01008 · Cited by 75
“In fact, gene therapy has been shown to be effective in genetically well-defined cases when it is applied in an adequate time frame (Maguire et al., 2008; Gorbatyuk et al., 2010).”
BackgroundLong-term Structural Outcomes of Late-stage RPE65 Gene Therapy
Gardiner, K. L., Cideciyan, A. V., Swider, M., Dufour, V. L., Sumaroka, A., Komáromy, A. M., Hauswirth, W. W., Iwabe, S., Jacobson, S. G., Beltran, W. A., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.013 · Cited by 67
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F., & Battaglia Parodi, M. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 67
Glaus, E., Schmid, F. M., Costa, R. D., Berger, W., & Neidhardt, J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.7 · Cited by 75
Li, M., Jayandharan, G. R., Li, B., Ling, C., Ma, W., Srivastava, A., & Zhong, L. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.005 · Cited by 67
“Thus, development of alternative vector systems, such as adeno-associated virus (AAV), needs to be pursued, given the proven safety of AAV vectors in several Phase I/II clinical trials (Bainbridge et al. , 2008; Cideciyan et al. , 2008; Hauswirth et al. , 2008; Maguire et al. , 2008).”
Testa, F., Rossi, S., Sodi, A., Passerini, I., Iorio, V. D., Corte, M. D., Banfi, S., Surace, E. M., Menchini, U., Auricchio, A., et al. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8201 · Cited by 73
Self-citationThe clinical evaluation of infantile nystagmus: What to do first and why
Bertsch, M., Floyd, M., Kehoe, T., Pfeifer, W. L., & Drack, A. V. (2017) · Ophthalmic Genetics · doi:10.1080/13816810.2016.1266667 · Cited by 75
Schmid, F. M., Glaus, E., Barthelmes, D., Fliegauf, M., Gaspar, H., Nürnberg, G., Nürnberg, P., Omran, H., Berger, W., & Neidhardt, J. (2011) · Human Mutation · doi:10.1002/humu.21509 · Cited by 74
Rab GTPase Prenylation Hierarchy and Its Potential Role in Choroideremia Disease
Köhnke, M., Delon, C., Hastie, M. L., Nguyen, U. T. T., Wu, Y., Waldmann, H., Goody, R. S., Gorman, J. J., & Alexandrov, K. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081758 · Cited by 74
Stem cells as source for retinal pigment epithelium transplantation
Bertolotti, E., Neri, A., Camparini, M., Macaluso, C., & Marigo, V. (2014) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2014.06.002 · Cited by 70
Leber's Hereditary Optic Neuropathy-Gene Therapy: From Benchtop to Bedside
Koilkonda, R. D., & Guy, J. (2011) · Journal of Ophthalmology · doi:10.1155/2011/179412 · Cited by 66
“That this may be possible is suggested by the Leber’s congenital amaurosis (LCA) clinical trials where partial return of visual function occurred even in eyes with severe and long-standing photoreceptor loss [97, 120, 121].”
BackgroundPapayannakos, C. J., & Daniel, R. (2012) · Gene Therapy · doi:10.1038/gt.2012.88 · Cited by 75
Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Self-citationIvanova, E., & Pan, Z. (2009) · PubMed Central · Cited by 82
RPE65, Visual Cycle Retinol Isomerase, Is Not Inherently 11-cis-specific
Redmond, T. M., Poliakov, E., Kuo, S., Chander, P., & Gentleman, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.027458 · Cited by 65
Self-citationSuppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
Askou, A. L., Alsing, S., Benckendorff, J. N. E., Holmgaard, A., Mikkelsen, J. G., Aagaard, L., Bek, T., & Corydon, T. J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.01.012 · Cited by 64
Stem cell therapy for retinal disease
Tibbetts, M. D., Samuel, M. A., Chang, T. S., & Ho, A. C. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328352407d · Cited by 69
RPE65 gene therapy slows cone loss in Rpe65-deficient dogs
Mowat, F. M., Breuwer, A. R., Bartoe, J. T., Annear, M. J., Zhang, Z., Smith, A. J., Bainbridge, J. W., Petersen‐Jones, S. M., & Ali, R. R. (2012) · Gene Therapy · doi:10.1038/gt.2012.63 · Cited by 70
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 65
“…that has shown beneficial results in treating inherited retinal disease [Bainbridge et al., 2008; Cideciyan et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008; Cideciyan et al., 2009; Maguire et al., 2009; Banin et al., 2010; Simonelli et al., 2010; Jacobson et al., 2012; Testa et al.,…”
BackgroundNavigating the current landscape of clinical genetic testing for inherited retinal dystrophies
Lee, K., & Garg, S. (2015) · Genetics in Medicine · doi:10.1038/gim.2015.15 · Cited by 72
Gene therapy for the regeneration of bone
Evans, C. H. (2011) · Injury · doi:10.1016/j.injury.2011.03.032 · Cited by 66
Li, X., Li, W., Dai, X., Kong, F., Zheng, Q., Zhou, X., Lü, F., Chang, B., Rohrer, B., Hauswirth, W. W., et al. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6138 · Cited by 64
Matching for Human Leukocyte Antigens (HLA) in corneal transplantation – To do or not to do
van Essen, T. H., Roelen, D. L., Williams, K. A., & Jager, M. J. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.01.001 · Cited by 65
Djilas, M., Olès, C., Lorach, H., Bendali, A., Dégardin, J., Dubus, E., Lissorgues-Bazin, G., Rousseau, L., Benosman, R., Ieng, S.-H., et al. (2011) · Journal of Neural Engineering · doi:10.1088/1741-2560/8/4/046020 · Cited by 65
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
Aronson, S. J., Veron, P., Collaud, F., Hubert, A., Delahais, V., Honnet, G., de Knegt, R. J., Junge, N., Baumann, U., Di Giorgio, A., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.143 · Cited by 65
Self-citationYe, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
“Previous studies in which humans received subretinal injections of AAV vector expressing RPE65 or REP1 employed a variety of postoperative dilating, antibiotic, and antiinflammatory regimens, including oral corticosteroids in some studies.(34,35) Results from the present nonclinical study suggest that oral corticoster…”
ResultCarvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Direct Comparison of Administration Routes for AAV8-mediated Ocular Gene Therapy
Igarashi, T., Miyake, K., Asakawa, N., Miyake, N., Shimada, T., & Takahashi, H. (2013) · Current Eye Research · doi:10.3109/02713683.2013.779720 · Cited by 64
Gene therapy for inherited retinal degenerations
Dalkara, D., & Sahel, J.-A. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2014.01.002 · Cited by 64
Leber Hereditary Optic Neuropathy: Exemplar of an mtDNA Disease
Wallace, D. C., & Lott, M. T. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_2 · Cited by 67
“Leber Congenital Amaurosis resulting from genetic inactivation of the nDNA RP65 gene has been successfully treated by sub-retinal injection of AAV2-hRPE65v2 (Maguire et al. 2008, 2009; Bennicelli et al. 2008; Amado et al. 2010; Simonelli et al. 2010; Bennett et al. 2012).”
BackgroundSuprachoroidal gene transfer with nonviral nanoparticles
Shen, J., Kim, J., Tzeng, S. Y., Ding, K., Hafiz, Z., Long, D., Wang, J., Green, J. J., & Campochiaro, P. A. (2020) · Science Advances · doi:10.1126/sciadv.aba1606 · Cited by 63
Changes in adeno-associated virus-mediated gene delivery in retinal degeneration
Kolstad, K. D., Dalkara, D., Guerin, K., Visel, M., Hoffmann, N., Schaffer, D. V., & Flannery, J. G. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.194 · Cited by 63
Cas9-directed immune tolerance in humans—a model to evaluate regulatory T cells in gene therapy?
Wagner, D. L., Peter, L., & Schmueck-Henneresse, M. (2021) · Gene Therapy · doi:10.1038/s41434-021-00232-2 · Cited by 63
Touchard, E., Berdugo, M., Bigey, P., El Sanharawi, M., Savoldelli, M., Naud, M.-C., Jeanny, J.-C., & Behar-Cohen, F. (2012) · Molecular Therapy · doi:10.1038/mt.2011.304 · Cited by 63
Peden, M. C., Min, J., Meyers, C., Lukowski, Z., Li, Q., Boye, S. L., Levine, M., Hauswirth, W. W., Ratnakaram, R., Dawson, W., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017140 · Cited by 63
“In both cases, it was concluded that the macular hole was likely due to a pre-existing epiretinal membrane contraction that was stimulated by the surgical procedure itself rather than the vector [2,5].”
BackgroundMethodInfluentialNon-viral strategies for delivering genome editing enzymes
Li, J., Røise, J. J., He, M., Das, R., & Murthy, N. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.09.004 · Cited by 68
Roman, A. J., Cideciyan, A. V., Wu, V., Garafalo, A. V., & Jacobson, S. G. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101000 · Cited by 63
Quantitative Analysis of Retinal Vessel Attenuation in Eyes with Retinitis Pigmentosa
Ma, Y., Kawasaki, R., Dobson, L. P., Ruddle, J. B., Kearns, L. S., Wong, T. Y., & Mackey, D. A. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8596 · Cited by 63
Zhang, T., Baehr, W., & Fu, Y. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9851 · Cited by 63
Jacobson, S. G., Cideciyan, A. V., Alemán, T. S., Sumaroka, A., Román, A. J., Świder, M., Schwartz, S., Banin, E., & Stone, E. M. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6127 · Cited by 72
Self-citationHydrogels for lentiviral gene delivery
Seidlits, S. K., Gower, R. M., Shepard, J. A., & Shea, L. D. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.764864 · Cited by 65
“Several viral vectors are currently being tested in clinical trials for various therapies, including retroviruses, lentiviruses, adenoviruses and adeno-associated viruses (AAVs) [1-4,14,21-26].”
BackgroundAshtari, M., Zhang, H., Cook, P. A., Cyckowski, L. L., Shindler, K. S., Marshall, K. A., Aravand, P., Vossough, A., Gee, J. C., Maguire, A. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8791 · Cited by 62
“LCA2 subjects had to meet strict inclusion/exclusion criteria to be invited to participate in the gene therapy trial (46, 47).”
InfluentialSelf-citationMotas, S., Haurigot, V., Garcia, M., Marcó, S., Ribera, A., Roca, C., Sánchez, X., Sánchez, V., Molas, M., Bertolin, J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.86696 · Cited by 71
Medical Management of Hereditary Optic Neuropathies
Morgia, C. L., Carbonelli, M., Barboni, P., Sadun, A. A., & Carelli, V. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00141 · Cited by 67
“For DOA, being a nuclear-encoded disease, gene therapy strategy should be more straightforward and feasible, as demonstrated by the recent encouraging results obtained with the gene therapy in Leber’s congenital amaurosis (78, 79).”
ResultNichols, L., Alur, R. P., Boobalan, E., Sergeev, Y. V., Caruso, R. C., Stone, E. M., Swaroop, A., Johnson, M. A., & Brooks, B. P. (2010) · Human Mutation · doi:10.1002/humu.21268 · Cited by 71
Self-citationGargiulo, A., Bonetti, C., Montefusco, S., Neglia, S., Di Vicino, U., Marrocco, E., Corte, M. D., Domenici, L., Auricchio, A., & Surace, E. M. (2009) · Molecular Therapy · doi:10.1038/mt.2009.112 · Cited by 61
Self-citationInherited retinal disease in Norway – a characterization of current clinical and genetic knowledge
Holtan, J. P., Selmer, K. K., Heimdal, K., & Bragadóttir, R. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14218 · Cited by 72
“…artificial retinal prostheses and pharmacological agents (Narfstrom et al. 2003; Hoffman et al. 2004; Bainbridge et al. 2008; Hauswirth et al. 2008; Maguire et al. 2008; Busskamp et al. 2010; Jinek et al. 2012; Klassen et al. 2012; Bennett et al. 2016; MacLaren et al. 2016; Stingl et al. 2017).”
BackgroundSystemic and local immune responses to intraocular AAV vector administration in non-human primates
Ail, D., Ren, D., Brazhnikova, E., Nouvel-Jaillard, C., Bertin, S., Mirashrafi, S. B., Fisson, S., & Dalkara, D. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.01.011 · Cited by 61
“24 March This is an open access article under the CC BY-NC-ND license (http tions in patients with Leber’s congenital amaurosis (LCA).(7,8) Following this success, there have been several completed or ongoing clinical trials for AAV-based gene therapy, particularly for eye diseases.”
BackgroundAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61
“These include a phospholipase A2 (PLA2) motif and 3 basic regions (BR1, 2, and 3), all of which putatively con-trol endosomal escape, nuclear localization, and nuclear import via the nuclear pore complex, respectively (27–31).”
Strategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“In clinical trials of Leber’s congenital amaurosis, AAVmediated delivery of the RPE65 gene by subretinal injection and successful correction of vision with no adverse effect after 5 years has been reported [33-36].”
BackgroundBinley, K., Widdowson, P. S., Kelleher, M., de Belin, J., Loader, J., Ferrige, G., Carlucci, M., Esapa, M., Chipchase, D., Angell-Manning, D., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.008 · Cited by 61
“Ocular gene therapy after subretinal delivery is already being evaluated in individuals with Leber congenital amaurosis (LCA), which is a group of hereditary retinal dystrophies characterized by severe loss of retinal and visual function (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
Evaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Wang, S. K., Xue, Y., Rana, P., Hong, C. M., & Cepko, C. L. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901787116 · Cited by 60
“While this approach has proven successful in other conditions, even leading to the approval of a gene therapy for RPE65-associated Leber’s congenital amaurosis (7), it is difficult to implement for the majority of patients with RP, given the extensive heterogeneity of the genetic lesions and the fact that a causal mut…”
BackgroundOptogenetic Therapy for Visual Restoration
Sakai, D., Tomita, H., & Maeda, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315041 · Cited by 68
Clinical applications of gene therapy for rare diseases: A review
Papaioannou, I., Owen, J. S., & Yáñez‐Muñoz, R. J. (2023) · International Journal of Experimental Pathology · doi:10.1111/iep.12478 · Cited by 79
Guziewicz, K. E., Zangerl, B., Komáromy, A. M., Iwabe, S., Chiodo, V. A., Boye, S. L., Hauswirth, W. W., Beltran, W. A., & Aguirre, G. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075666 · Cited by 61
“Successful outcomes from the first clinical trials in patients affected with RPE65 form of LCA were reported and have shown safety and efficacy [15–18].”
BackgroundMutation Discovered in a Feline Model of Human Congenital Retinal Blinding Disease
Menotti-Raymond, M. A., Deckman, K. H., David, V. A., Myrkalo, J., O’Brien, S. J., & Narfström, K. L. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4261 · Cited by 65
Metabolite therapy guided by liquid biopsy proteomics delays retinal neurodegeneration
Wert, K. J., Velez, G., Vijayalakshmi, K., Shankar, V., Evans, L. P., Sengillo, J. D., Zare, R. N., Bassuk, A. G., Tsang, S. H., & Mahajan, V. B. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102636 · Cited by 64
“advances to treat RP patients using prosthetics or gene therapy approaches [9-12], but only end-stage RP or patients with the RPE65 gene mutation, respectively, are currently eligible for such therapies.”
BackgroundZhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60
“Recent reports on the success of clinical trials of gene therapy for RPE65-LCA and choroideremia have provided considerable excitement in the field of AAV-mediated gene delivery into the diseased retina.(28,30,46) However, progress in the development of mutation-independent gene replacement strategies for CEP290-LCA h…”
BackgroundFuruta-Hanawa, B., Yamaguchi, T., & Uchida, E. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.031 · Cited by 60
MicroRNA-Restricted Transgene Expression in the Retina
Karali, M., Manfredi, A., Puppo, A., Marrocco, E., Gargiulo, A., Allocca, M., Corte, M. D., Rossi, S., Giunti, M., Bacci, M. L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022166 · Cited by 60
“The safety and efficacy of AAV-based gene therapy has been verified in various animal models [13] and in humans [14,15,16,17,18,19,20,21].”
BackgroundSelf-citationMechanisms of blindness: Animal models provide insight into distinct CRX ‐associated retinopathies
Tran, N. M., & Chen, S. (2014) · Developmental Dynamics · doi:10.1002/dvdy.24151 · Cited by 64
Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors
Krishnamurthy, S., Traore, S., Cooney, A. L., Brommel, C. M., Kulhánková, K., Sinn, P. L., Newby, G. A., Liu, D. R., & McCray, P. B. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab788 · Cited by 66
Native Molecular State of Adeno-Associated Viral Vectors Revealed by Single-Molecule Sequencing
Kapranov, P., Chen, L., Dederich, D., Dong, B., He, J., Steinmann, K. E., Moore, A. R., Thompson, J. F., Milos, P. M., & Xiao, W. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.160 · Cited by 60
“…of rAAV genomes remain unclear, and despite extensive research and deployment of AAV-based vectors for gene therapy applications (Manno et al. , 2006; Maguire et al. , 2008, 2009), basic questions about AAV biology, which are the key to further improvements in its application as a vector, remain.”
High, K. A., & Aubourg, P. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_18 · Cited by 60
Self-citationBarker, S. E., Broderick, C. A., Robbie, S. J., Duran, Y., Natkunarajah, M., Buch, P., Balaggan, K. S., MacLaren, R. E., Bainbridge, J. W. B., Smith, A. J., et al. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1327 · Cited by 59
“However, to date, there does not appear to have been any detailed analysis of cellular and humoural immune responses following intraocular administration of AAV, and what effect these responses may have on repeat administration of vector; this information is critical because ocular gene therapy clinical trials are now…”
BackgroundCiulla, T. A., Hussain, R. M., Berrocal, A. M., & Nagiel, A. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1740676 · Cited by 59
Woodard, K. T., Liang, K. J., Bennett, W. C., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.01568-16 · Cited by 59
Gene-Based Therapeutics for Inherited Retinal Diseases
Fenner, B. J., Tan, T.-E., Barathi, A. V., Tun, S. B. B., Yeo, S. W., Tsai, A. S. H., Lee, S. Y., Cheung, C. M. G., Chan, C. M., Mehta, J. S., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2021.794805 · Cited by 59
“6 kb coding sequence of RPE65 was placed under the control of a modified avian β-actin promoter with a cytomegalovirus enhancer sequence (Maguire et al., 2008; Maguire et al., 2009).”
MethodHenriques, A., Pitzer, C., Dittgen, T., Klugmann, M., Dupuis, L., & Schneider, A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.271 · Cited by 59
Boye, S. L., Peshenko, I. V., Huang, W. C., Min, S. H., McDoom, I., Kay, C. N., Liu, X., Dyka, F. M., Foster, T. C., Umino, Y., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.193 · Cited by 58
Dog Models for Blinding Inherited Retinal Dystrophies
Petersen-Jones, S. M., & Komáromy, A. M. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.155 · Cited by 59
Anti-angiogenic Therapy for Retinal Disease
Paulus, Y. M., & Sodhi, A. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_78 · Cited by 59
“Gene therapy trials have been completed for Leber’s congenital amaurosis and have shown safety and promising results (Maguire et al. 2008).”
BackgroundPatrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 59
Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector
Barnard, A. R., Groppe, M., & MacLaren, R. E. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017293 · Cited by 60
“CBA promoters have provided highly effective transduction in retinal gene therapy clinical trials (Hauswirth et al. 2008; Maguire et al. 2008) and appear to sustain expression for over a decade in dogs (Bennicelli et al. 2008; Cideciyan et al. 2013) and at least 3 yr in humans (Jacobson et al.…”
BackgroundMethodInfluentialMashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., & Pedraz, J. L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.010 · Cited by 58
Gene therapy matures in the clinic
Seymour, L. W., & Thrasher, A. J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2290 · Cited by 62
Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease
Zimmermann, M., Lubinga, S. J., Banken, R., Rind, D., Cramer, G., Synnott, P. G., Chapman, R. H., Khan, S., & Carlson, J. (2019) · Value in Health · doi:10.1016/j.jval.2018.09.2841 · Cited by 58
Innate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 68
Leach, L. L., & Clegg, D. (2015) · Stem Cells · doi:10.1002/stem.2010 · Cited by 62
Gene supplementation therapy for recessive forms of inherited retinal dystrophies
Smith, A. J., Bainbridge, J. W., & Ali, R. R. (2011) · Gene Therapy · doi:10.1038/gt.2011.161 · Cited by 66
Lorenz, B., Strohmayr, E., Zahn, S., Friedburg, C., Kramer, M., Preising, M. N., & Stieger, K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9974 · Cited by 65
The physiological impact of microRNA gene regulation in the retina
Sundermeier, T. R., & Palczewski, K. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-0976-7 · Cited by 59
Cheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G. V., Park, M., Stacpoole, P. W., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 59
Animal models and different therapies for treatment of retinitis pigmentosa.
Rivas, M. A., & Vecino, E. (2009) · PubMed · doi:10.14670/hh-24.1295 · Cited by 77
Metadata
- Authors
- Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., Rossi, S., Lyubarsky, A., Arruda, V. R., Konkle, B., Stone, E., Sun, J., Jacobs, J., Dell'Osso, L., Hertle, R., Ma, J.-X., Redmond, T. M., Zhu, X., Hauck, B., Zelenaia, O., Shindler, K. S., Maguire, M. G., Wright, J. F., Volpe, N. J., McDonnell, J. W., Auricchio, A., High, K. A., & Bennett, J.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Telethon Institute Of Genetics And Medicine (IT)
- University of Pennsylvania (US)
- University of Iowa (US)
- Veterans Health Administration (US)
- Children's Hospital of Pittsburgh (US)
- University of Oklahoma (US)
- National Eye Institute (US)
- ORCID
- Maguire, Albert M.
- Simonelli, Francesca
- Pierce, Eric A.
- Pugh, Edward N.
- Mingozzi, Federico
- Banfi, Sandro
- Testa, Francesco
- Surace, Enrico M.
- Rossi, Settimio
- Arruda, Valder R.
- Konkle, Barbara
- Stone, Edwin
- Sun, Junwei
- Hertle, Richard
- Ma, Jian-xing
- Redmond, T. Michael
- Zhu, Xiaosong
- Shindler, Kenneth S.
- Maguire, Maureen G.
- Wright, J. Fraser
- Volpe, Nicholas J.
- Auricchio, Alberto
- High, Katherine A.
- Bennett, Jean
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2240-2248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC2829748
- OpenAlex
- W2137222303
- Cited by
- 2,145
- References
- 27
- Citations by year
- 2026: 38 · 2025: 68 · 2024: 51 · 2023: 66 · 2022: 79 · 2021: 110 · 2020: 96 · 2019: 98 · 2018: 118 · 2017: 144 · 2016: 124 · 2015: 172 · 2014: 152 · 2013: 155 · 2012: 158
- FWCI
- 70.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Eye Institute (EY10820, R01EY010820)
- National Center for Research Resources (UL1RR024134)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, adeno-associated virus vectors, retinal pigment epithelium, macular hole, visual acuity, retinal function, adverse events, inherited retinal degeneration
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Promoter Regions, Genetic, Reflex, Pupillary, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.